Payment overview · 2025
General Payments
$206.44
4 reported records · 3 companies
Healthcare provider profile · identity verified
Alan J Yesner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FT LAUDERDALE, FL · NPI 1336182401
Verified facts
What the public records show
CMS Open Payments records show Alan J Yesner, M.D. received $206.44 in general payments during 2025 across 4 reported records.
ARGON MEDICAL DEVICES, INC. accounted for 71.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $147.16 | 71.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.00 | 19.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.28 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.44 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $147.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 840 | 249 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 751 | 223 |
| Atorvastatin Calcium | Atorvastatin Calcium | 606 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 129 |
| Losartan Potassium | Losartan Potassium | 440 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 72 |
| Alprazolam | Alprazolam | 225 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 77 |
| Gabapentin | Gabapentin | 221 | 72 |
| Metformin Hcl | Metformin Hcl | 212 | 68 |
| Clonazepam | Clonazepam | 210 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 67 |
| Trazodone Hcl | Trazodone Hcl | 210 | 58 |
| Eliquis | Apixaban | 190 | 47 |
| Valsartan | Valsartan | 185 | 55 |
| Ezetimibe | Ezetimibe | 164 | 51 |
| Potassium Chloride | Potassium Chloride | 158 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 40 |
| Temazepam | Temazepam | 137 | 34 |
| Lisinopril | Lisinopril | 129 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 34 |
| Lorazepam | Lorazepam | 121 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 115 | 35 |
| Simvastatin | Simvastatin | 115 | 36 |
| Omeprazole | Omeprazole | 108 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 33 |
| Famotidine | Famotidine | 96 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 34 |
| Montelukast Sodium | Montelukast Sodium | 95 | 29 |
| Allopurinol | Allopurinol | 90 | 30 |
| Ozempic | Semaglutide | 86 | 12 |
| Nifedipine Er | Nifedipine | 84 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 29 |
| Sertraline Hcl | Sertraline Hcl | 80 | 31 |
| Baclofen | Baclofen | 78 | 24 |
| Tramadol Hcl | Tramadol Hcl | 78 | 27 |
| Torsemide | Torsemide | 76 | 27 |
| Alendronate Sodium | Alendronate Sodium | 75 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 22 |
| Azithromycin | Azithromycin | 74 | 66 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 22 |
| Jardiance | Empagliflozin | 66 | 17 |
| Clonidine Hcl | Clonidine Hcl | 64 | 23 |
| Fenofibrate | Fenofibrate | 63 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 63 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 18 |
| Carvedilol | Carvedilol | 61 | 21 |
| Spironolactone | Spironolactone | 58 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Bumetanide | Bumetanide | 51 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 20 |
| Prednisone | Prednisone | 51 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 25 |
| Glipizide | Glipizide | 45 | 11 |
| Meloxicam | Meloxicam | 44 | 16 |
| Januvia | Sitagliptin Phosphate | 43 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Fenofibrate | Fenofibrate,micronized | 42 | 11 |
| Risedronate Sodium | Risedronate Sodium | 42 | 15 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 14 |
| Furosemide | Furosemide | 37 | 15 |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 11 |
| Glipizide Er | Glipizide | 36 | 14 |
| Midodrine Hcl | Midodrine Hcl | 36 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 11 |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | 11 |
| Cephalexin | Cephalexin | 29 | 24 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Lactulose | Lactulose | 26 | 13 |
| Meclizine Hcl | Meclizine Hcl | 26 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 26 | 14 |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 20 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.44 · 4 records | ARGON MEDICAL DEVICES, INC. | CLOT MANAGEMENT, ELIQUIS, Leqembi, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error